Published by:
Panaccione R, et al. Abstract LB11. Presented at: UEG Week; Oct. 3-5, 2021 (virtual meeting).
Read next
VIDEO: Rinvoq safe, effective as UC maintenance therapy
Published by:
Panaccione R, et al. Abstract LB11. Presented at: UEG Week; Oct. 3-5, 2021 (virtual meeting).
Click Here to Manage Email Alerts
Remo Panaccione, MD, of the University of Calgary, reported Rinvoq safely and effectively maintained moderate-to-severe ulcerative colitis.
“Upadacitinib, which is on the market as Rinvoq [AbbVie] for rheumatoid arthritis, is expected to be approved in 2022 for the treatment of moderate to severe ulcerative colitis,” Panaccione said. “Seeing these impressive efficacy results and these striking differences over placebo bodes well for us as prescribers and for patients going forward with moderate to severe ulcerative colitis.”